ADIL
Adial Pharmaceuticals Inc
NASDAQ: ADIL · HEALTHCARE · BIOTECHNOLOGY
$1.44
-8.68% today
Updated 2026-06-05
Market cap
$5.25M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.89
Dividend yield
—
52W range
$1 – $19
Volume
0.1M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.8
Quality
C+3.0
Profitability
D5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-19.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$25.00
+1636.11%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z -19.39 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-1.61M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-12.73M | $-7.00M | $-13.20M | $-7.98M | $-2.02M |
| EPS | — | — | — | — | $-4.89 |
| Free cash flow | $-11.19M | $-13.61M | $-6.92M | $-6.49M | $-1.61M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Adial Pharmaceuticals Inc trades at $1.44. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -19.39, it sits in the distress.
Frequently asked questions
What is Adial Pharmaceuticals Inc's stock price?
Adial Pharmaceuticals Inc (ADIL) trades at $1.44.
Is Adial Pharmaceuticals Inc overvalued?
Adial Pharmaceuticals Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Adial Pharmaceuticals Inc (ADIL)?
The 12-month analyst consensus target is $25.00, about 1636.1% above the current $1.44. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Adial Pharmaceuticals Inc's Altman Z-Score is -19.39, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-209.05%
Beta1.27
50D MA$1.73
200D MA$5.51
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—